Boehringer Ingelheim
Robert Buchberger MD PhD has extensive experience in the field of pharmacovigilance and risk management. Robert began their career in 1995 as a Clinical Psychiatrist at the University of Hamburg. From 1999 to 2010, they held various roles at Solvay Pharmaceuticals, including Global Head Pharmacovigilance Operations and Deputy EU QPPV. In 2010, they joined Abbott as Senior Vice President Global Pharmacovigilance & Risk Management, EU QPPV. Robert then moved on to Boehringer Ingelheim in 2011, where they are currently serving as Corporate Senior Vice President and Global Head of Patient Safety & Pharmacovigilance.
Robert Buchberger MD PhD completed their education at Ludwig-Maximilians-Universität München where they earned their Medical Doctor degree from 1987 to 1993. In 2008, they also attended the London Business School for a Senior Executive Programme.
This person is not in any offices
Boehringer Ingelheim
112 followers
At Boehringer Ingelheim they create value through innovation with one clear goal: to improve the lives of patients. They develop breakthrough therapies and innovative healthcare solutions in areas of unmet medical need for both humans and animals. As a family owned company, they focus on long-term performance. They are powered by 50.000 employees globally who nurture a diverse, collaborative and inclusive culture. Learning and development for all employees is key, because your growth is their growth.